Subgroups of Parotid Gland Infiltrating Ductal Carcinoma Benefit from Postoperative Radiotherapy: A Population-Based Study

References

• Osborn V , GiviB, LeeAet al. Characterization, treatment and outcomes of salivary ductal carcinoma using the National Cancer Database. Oral Oncol.71, 41–46 (2017).
   PubMed Web of Science ®Google Scholar
• Otsuka K , ImanishiY, TadaYet al. Clinical outcomes and prognostic factors for salivary duct carcinoma: a multi-institutional analysis of 141 patients. Ann. Surg. Oncol.23(6), 2038–2045 (2016).
   PubMed Web of Science ®Google Scholar
• Boon E , BelM, Van BoxtelWet al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int. J. Cancer143(4), 758–766 (2018).
   PubMed Web of Science ®Google Scholar
• Kim TH , KimMS, ChoiSHet al. Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience. Radiat. Oncol. J.32(3), 125–131 (2014).
   PubMedGoogle Scholar
• Han MW , RohJL, ChoiSHet al. Prognostic factors and outcome analysis of salivary duct carcinoma. Auris Nasus Larynx42(6), 472–477 (2015).
   PubMed Web of Science ®Google Scholar
• D’Heygere E , MeulemansJ, Vander PoortenV. Salivary duct carcinoma. Curr. Opin. Otolaryngol. Head Neck Surg.26(2), 142–151 (2018).
   PubMed Web of Science ®Google Scholar
• Pons Y , AlvesA, ClementP, ConessaC. Salivary duct carcinoma of the parotid gland. Eur. Ann. Otorhinolaryngol. Head Neck Dis.128(4), 194–196 (2011).
   PubMed Web of Science ®Google Scholar
• Jayaprakash V , MerzianuM, WarrenGWet al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. Head Neck36(5), 694–701 (2014).
   PubMed Web of Science ®Google Scholar
• Al-Qahtani KH , TunioMA, BayoumiY, GurusamyVM, BahamdainFA, FataniH. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland. J. Otolaryngol. Head Neck Surg.45(1), 32 (2016).
   PubMedGoogle Scholar
• Salovaara E , HakalaO, BackLet al. Management and outcome of salivary duct carcinoma in major salivary glands. Eur. Arch. Otorhinolaryngol.270(1), 281–285 (2013).
   PubMed Web of Science ®Google Scholar
• Honda K , TanakaS, ShinoharaSet al. Survival in patients with parotid gland carcinoma – results of a multi-center study. Am. J. Otolaryngol.39(1), 65–70 (2018).
   PubMed Web of Science ®Google Scholar
• Qian K , DiL, GuoK, ZhengX, JiQ, WangZ. Cervical lymph node metastatic status and adjuvant therapy predict the prognosis of salivary duct carcinoma. J. Oral Maxillofac. Surg.76(7), 1578–1586 (2018).
   PubMed Web of Science ®Google Scholar
• SEER. Overview of the SEER Program . https://seer.cancer.gov/about/overview.html
   Google Scholar
• Beck ACC , LohuisP, Al-MamganiA, SmitLA, KlopWMC. Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute. Eur. Arch. Otorhinolaryngol.275(7), 1885–1892 (2018).
   PubMed Web of Science ®Google Scholar
• Dalin MG , DesrichardA, KatabiNet al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin. Cancer Res.22(18), 4623–4633 (2016).
   PubMed Web of Science ®Google Scholar
• Sato F , AkibaJ, KawaharaAet al. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. J. Oral Pathol. Med.47(7), 683–690 (2018).
   PubMed Web of Science ®Google Scholar
• Jalaly JB , SanatiS, ChernockRD, DibeDG, El-MoftySK. Salivary duct carcinoma and invasive ductal carcinoma of the breast: a comparative immunohistochemical study. Head Neck Pathol.12(4), 488–492 (2018).
   PubMedGoogle Scholar
• Lee JS , KwonOJ, ParkJJ, SeoJH. Salivary duct carcinoma of the parotid gland: is adjuvant HER-2-targeted therapy required?J. Oral Maxillofac. Surg.72(5), 1023–1031 (2014).
   PubMed Web of Science ®Google Scholar
• Schmitt NC , KangH, SharmaA. Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy. Oral Oncol.74, 40–48 (2017).
   PubMed Web of Science ®Google Scholar
• Wee DT , ThomasAA, BradleyPJ. Salivary duct carcinoma: what is already known, and can we improve survival?J. Laryngol. Otol.126(Suppl. 2), S2–S7 (2012).
   PubMedGoogle Scholar
• Di Palma S , SimpsonRH, MarchioCet al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. Histopathology61(4), 629–643 (2012).
   PubMed Web of Science ®Google Scholar
• Goh I , LaiO, ChewL. Prevalence and risk of polypharmacy among elderly cancer patients receiving chemotherapy in ambulatory oncology setting. Curr. Oncol. Rep.20(5), 38 (2018).
   PubMed Web of Science ®Google Scholar
• Yeoh TT , TayXY, SiP, ChewL. Drug-related problems in elderly patients with cancer receiving outpatient chemotherapy. J. Geriatr. Oncol.6(4), 280–287 (2015).
   PubMed Web of Science ®Google Scholar
• Petkar I , RooneyK, RoeJWet al. DARS: a Phase III randomised multicentre study of dysphagia-optimised intensity-modulated radiotherapy (Do-IMRT) versus standard intensity-modulated radiotherapy (S-IMRT) in head and neck cancer. BMC Cancer16(1), 770 (2016).
   PubMedGoogle Scholar
• Ghosh-Laskar S , YathirajPH, DuttaDet al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: long-term results. Head Neck38(Suppl. 1), e1481–e1487 (2016).
   PubMed Web of Science ®Google Scholar
• Nuyts S , LambrechtM, DuprezFet al. Reduction of the dose to the elective neck in head and neck squamous cell carcinoma, a randomized clinical trial using intensity modulated radiotherapy (IMRT). Dosimetrical analysis and effect on acute toxicity. Radiother. Oncol.109(2), 323–329 (2013).
   PubMed Web of Science ®Google Scholar
• Gupta T , AgarwalJ, JainSet al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother. Oncol.104(3), 343–348 (2012).
   PubMed Web of Science ®Google Scholar